| # | Pathway | Proteins |
|---|
| 1 | Salmonella infection | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000009311, ENSAPLP00000005955, ENSAPLP00000006991 |
| 2 | Systemic lupus erythematosus | ENSAPLP00000011395, ENSAPLP00000001729, ENSAPLP00000011291, ENSAPLP00000001720, ENSAPLP00000013019, ENSAPLP00000005500 |
| 3 | Vascular smooth muscle contraction | ENSAPLP00000005411, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000015007, ENSAPLP00000002381, ENSAPLP00000013090 |
| 4 | Malaria | ENSAPLP00000016307, ENSAPLP00000015337, ENSAPLP00000007488 |
| 5 | African trypanosomiasis | ENSAPLP00000016307, ENSAPLP00000011291, ENSAPLP00000007488 |
| 6 | Tight junction | ENSAPLP00000007261, ENSAPLP00000013019, ENSAPLP00000012466, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000013090 |
| 7 | Dilated cardiomyopathy | ENSAPLP00000012522, ENSAPLP00000011291, ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000003991 |
| 8 | Primary bile acid biosynthesis | ENSAPLP00000002356, ENSAPLP00000014205 |
| 9 | Regulation of actin cytoskeleton | ENSAPLP00000009727, ENSAPLP00000003050, ENSAPLP00000005411, ENSAPLP00000013019, ENSAPLP00000005955, ENSAPLP00000006991, ENSAPLP00000013090 |
| 10 | Vitamin digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 11 | Hypertrophic cardiomyopathy (HCM) | ENSAPLP00000012522, ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000003991 |
| 12 | Cardiac muscle contraction | ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000003991 |
| 13 | Fat digestion and absorption | ENSAPLP00000011529, ENSAPLP00000003561 |
| 14 | Alcoholism | ENSAPLP00000011395, ENSAPLP00000001729, ENSAPLP00000001720, ENSAPLP00000005500 |
| 15 | Calcium signaling pathway | ENSAPLP00000012279, ENSAPLP00000011291, ENSAPLP00000005411, ENSAPLP00000009427 |
| 16 | cGMP-PKG signaling pathway | ENSAPLP00000012279, ENSAPLP00000005411, ENSAPLP00000009427, ENSAPLP00000013090 |
| 17 | Focal adhesion | ENSAPLP00000008118, ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000005411, ENSAPLP00000013019, ENSAPLP00000009311, ENSAPLP00000013090 |
| 18 | Taurine and hypotaurine metabolism | ENSAPLP00000014205 |
| 19 | Amoebiasis | ENSAPLP00000008118, ENSAPLP00000011291, ENSAPLP00000013019, ENSAPLP00000004050 |
| 20 | VEGF signaling pathway | ENSAPLP00000003050, ENSAPLP00000004050 |
| 21 | Asthma | ENSAPLP00000011291 |
| 22 | MAPK signaling pathway | ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000009311, ENSAPLP00000004050 |
| 23 | B cell receptor signaling pathway | ENSAPLP00000011291, ENSAPLP00000003050 |
| 24 | Parkinson's disease | ENSAPLP00000012279, ENSAPLP00000009300, ENSAPLP00000009427, ENSAPLP00000010540 |
| 25 | Type I diabetes mellitus | ENSAPLP00000004358 |
| 26 | Adrenergic signaling in cardiomyocytes | ENSAPLP00000012136, ENSAPLP00000003219, ENSAPLP00000003991 |
| 27 | Natural killer cell mediated cytotoxicity | ENSAPLP00000011291, ENSAPLP00000003050 |
| 28 | Fc epsilon RI signaling pathway | ENSAPLP00000011291, ENSAPLP00000003050 |
| 29 | Viral carcinogenesis | ENSAPLP00000003050, ENSAPLP00000001720, ENSAPLP00000013019, ENSAPLP00000005500 |
| 30 | Allograft rejection | ENSAPLP00000011291 |
| 31 | Viral myocarditis | ENSAPLP00000011291, ENSAPLP00000003050 |
| 32 | PPAR signaling pathway | ENSAPLP00000005715, ENSAPLP00000010482 |
| 33 | Protein digestion and absorption | ENSAPLP00000008118, ENSAPLP00000012993 |
| 34 | Intestinal immune network for IgA production | ENSAPLP00000011291 |
| 35 | Phenylalanine metabolism | ENSAPLP00000005038 |
| 36 | Osteoclast differentiation | ENSAPLP00000013336, ENSAPLP00000003050 |
| 37 | Primary immunodeficiency | ENSAPLP00000011291 |
| 38 | Dorso-ventral axis formation | ENSAPLP00000016323 |
| 39 | Autoimmune thyroid disease | ENSAPLP00000011291 |
| 40 | Leukocyte transendothelial migration | ENSAPLP00000003050, ENSAPLP00000013019, ENSAPLP00000013090 |
| 41 | Ribosome | ENSAPLP00000005418, ENSAPLP00000007620, ENSAPLP00000004797, ENSAPLP00000004439 |
| 42 | Peroxisome | ENSAPLP00000014205, ENSAPLP00000006873 |
| 43 | Histidine metabolism | ENSAPLP00000003438 |
| 44 | Biosynthesis of unsaturated fatty acids | ENSAPLP00000014205 |
| 45 | Shigellosis | ENSAPLP00000009727, ENSAPLP00000003050 |
| 46 | Bile secretion | ENSAPLP00000014205 |
| 47 | Regulation of lipolysis in adipocytes (no map in kegg database) | ENSAPLP00000005715 |
| 48 | Notch signaling pathway | ENSAPLP00000016323 |
| 49 | p53 signaling pathway | ENSAPLP00000003567 |
| 50 | Huntington's disease | ENSAPLP00000012279, ENSAPLP00000009300, ENSAPLP00000016247, ENSAPLP00000009427 |
| 51 | Proteoglycans in cancer | ENSAPLP00000003050, ENSAPLP00000003837, ENSAPLP00000004439, ENSAPLP00000009311 |
| 52 | Porphyrin and chlorophyll metabolism | ENSAPLP00000007495 |
| 53 | Wnt signaling pathway | ENSAPLP00000003050, ENSAPLP00000011840 |
| 54 | Fc gamma R-mediated phagocytosis | ENSAPLP00000011291, ENSAPLP00000003050 |
| 55 | Complement and coagulation cascades | ENSAPLP00000010484, ENSAPLP00000003063 |
| 56 | N-Glycan biosynthesis | ENSAPLP00000006600 |
| 57 | cAMP signaling pathway | ENSAPLP00000003050, ENSAPLP00000013090 |
| 58 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ENSAPLP00000012522, ENSAPLP00000013019 |
| 59 | Adherens junction | ENSAPLP00000003050, ENSAPLP00000013019 |
| 60 | mTOR signaling pathway | ENSAPLP00000004439 |
| 61 | Hematopoietic cell lineage | ENSAPLP00000011291 |
| 62 | PI3K-Akt signaling pathway | ENSAPLP00000008118, ENSAPLP00000011291, ENSAPLP00000003050, ENSAPLP00000004439 |
| 63 | Tyrosine metabolism | ENSAPLP00000005038 |
| 64 | Colorectal cancer | ENSAPLP00000003050 |
| 65 | Steroid hormone biosynthesis | ENSAPLP00000002356 |
| 66 | Leishmaniasis | ENSAPLP00000011291 |
| 67 | Tuberculosis | ENSAPLP00000011291, ENSAPLP00000004358 |
| 68 | NF-kappa B signaling pathway | ENSAPLP00000011291 |
| 69 | beta-Alanine metabolism | ENSAPLP00000010482 |
| 70 | Pancreatic cancer | ENSAPLP00000003050 |
| 71 | Staphylococcus aureus infection | ENSAPLP00000011291 |
| 72 | Oxytocin signaling pathway | ENSAPLP00000005411, ENSAPLP00000013090 |
| 73 | Legionellosis | ENSAPLP00000004358 |
| 74 | Rheumatoid arthritis | ENSAPLP00000011291 |
| 75 | Apoptosis | ENSAPLP00000009010 |
| 76 | Insulin signaling pathway | ENSAPLP00000015750, ENSAPLP00000004439 |
| 77 | Toll-like receptor signaling pathway | ENSAPLP00000003050 |
| 78 | Amyotrophic lateral sclerosis (ALS) | ENSAPLP00000003050 |
| 79 | Endocrine and other factor-regulated calcium reabsorption | ENSAPLP00000016247 |
| 80 | Pancreatic secretion | ENSAPLP00000003050 |
| 81 | MicroRNAs in cancer | ENSAPLP00000016323, ENSAPLP00000003219 |
| 82 | Choline metabolism in cancer | ENSAPLP00000003050 |
| 83 | Transcriptional misregulation in cancer | ENSAPLP00000011291 |
| 84 | Propanoate metabolism | ENSAPLP00000010482 |
| 85 | HTLV-I infection | ENSAPLP00000012279, ENSAPLP00000009427 |
| 86 | Renal cell carcinoma | ENSAPLP00000003050 |
| 87 | Arginine and proline metabolism | ENSAPLP00000010692 |
| 88 | Measles | ENSAPLP00000011291 |
| 89 | Synaptic vesicle cycle | ENSAPLP00000016247 |
| 90 | Gastric acid secretion | ENSAPLP00000005411 |
| 91 | Epithelial cell signaling in Helicobacter pylori infection | ENSAPLP00000003050 |
| 92 | Prion diseases (no map in kegg database) | ENSAPLP00000016323 |
| 93 | Fatty acid metabolism (no map in kegg database) | ENSAPLP00000010482 |
| 94 | Rap1 signaling pathway | ENSAPLP00000009727, ENSAPLP00000003050 |
| 95 | Fatty acid degradation | ENSAPLP00000010482 |
| 96 | RNA degradation | ENSAPLP00000004358 |
| 97 | Lysosome | ENSAPLP00000014136, ENSAPLP00000009330 |
| 98 | Alzheimer's disease | ENSAPLP00000015337, ENSAPLP00000009300 |
| 99 | Phagosome | ENSAPLP00000011291, ENSAPLP00000003050 |
| 100 | Small cell lung cancer | ENSAPLP00000008118 |
| 101 | Sphingolipid signaling pathway | ENSAPLP00000003050 |
| 102 | Phospholipase D signaling pathway | ENSAPLP00000011291 |
| 103 | Thyroid hormone signaling pathway | ENSAPLP00000016323 |
| 104 | Valine, leucine and isoleucine degradation | ENSAPLP00000010482 |
| 105 | Epstein-Barr virus infection | ENSAPLP00000011291, ENSAPLP00000004050 |
| 106 | HIF-1 signaling pathway | ENSAPLP00000004439 |
| 107 | Neurotrophin signaling pathway | ENSAPLP00000003050 |
| 108 | Influenza A (no map in kegg database) | ENSAPLP00000009427 |
| 109 | Axon guidance | ENSAPLP00000003050 |
| 110 | ECM-receptor interaction | ENSAPLP00000008118 |
| 111 | Herpes simplex infection | ENSAPLP00000015609 |
| 112 | Non-alcoholic fatty liver disease (NAFLD) | ENSAPLP00000003050 |
| 113 | Ras signaling pathway | ENSAPLP00000003050 |
| 114 | Chemokine signaling pathway | ENSAPLP00000003050 |
| 115 | Bacterial invasion of epithelial cells | ENSAPLP00000003050 |
| 116 | Platelet activation | ENSAPLP00000005411 |
| 117 | Oxidative phosphorylation | ENSAPLP00000009300 |
| 118 | Protein processing in endoplasmic reticulum | ENSAPLP00000006600 |
| 119 | Endocytosis | ENSAPLP00000016247, ENSAPLP00000005705 |
| 120 | Pathways in cancer | ENSAPLP00000008118, ENSAPLP00000003050 |
| 121 | Carbon metabolism (no map in kegg database) | ENSAPLP00000010482 |
| 122 | Metabolic pathways (no map in kegg database) | ENSAPLP00000006600, ENSAPLP00000009300, ENSAPLP00000002356, ENSAPLP00000014205, ENSAPLP00000010692, ENSAPLP00000010482 |